1. Home
  2. RFI vs ALLO Comparison

RFI vs ALLO Comparison

Compare RFI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RFI
  • ALLO
  • Stock Information
  • Founded
  • RFI 1992
  • ALLO 2017
  • Country
  • RFI United States
  • ALLO United States
  • Employees
  • RFI N/A
  • ALLO N/A
  • Industry
  • RFI Investment Managers
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RFI Finance
  • ALLO Health Care
  • Exchange
  • RFI Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • RFI 313.7M
  • ALLO 252.9M
  • IPO Year
  • RFI N/A
  • ALLO 2018
  • Fundamental
  • Price
  • RFI $11.51
  • ALLO $1.28
  • Analyst Decision
  • RFI
  • ALLO Buy
  • Analyst Count
  • RFI 0
  • ALLO 12
  • Target Price
  • RFI N/A
  • ALLO $8.80
  • AVG Volume (30 Days)
  • RFI 69.8K
  • ALLO 2.9M
  • Earning Date
  • RFI 01-01-0001
  • ALLO 11-06-2025
  • Dividend Yield
  • RFI 8.25%
  • ALLO N/A
  • EPS Growth
  • RFI N/A
  • ALLO N/A
  • EPS
  • RFI N/A
  • ALLO N/A
  • Revenue
  • RFI N/A
  • ALLO N/A
  • Revenue This Year
  • RFI N/A
  • ALLO N/A
  • Revenue Next Year
  • RFI N/A
  • ALLO $100.00
  • P/E Ratio
  • RFI N/A
  • ALLO N/A
  • Revenue Growth
  • RFI N/A
  • ALLO N/A
  • 52 Week Low
  • RFI $9.62
  • ALLO $0.86
  • 52 Week High
  • RFI $12.52
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • RFI 36.70
  • ALLO 49.56
  • Support Level
  • RFI $11.37
  • ALLO $1.21
  • Resistance Level
  • RFI $11.93
  • ALLO $1.31
  • Average True Range (ATR)
  • RFI 0.13
  • ALLO 0.07
  • MACD
  • RFI -0.03
  • ALLO -0.01
  • Stochastic Oscillator
  • RFI 30.04
  • ALLO 26.39

About RFI Cohen & Steers Total Return Realty Fund Inc.

Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: